Everything below concerns anti-doping testing. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
=== Creationism === Crick was a firm critic of young Earth creationism. In the 1987 United States Supreme Court case Edwards v. Aguillard, Crick joined a group of other Nobel laureates who advised, "'Creation-science' simply has no place in the public-school science classroom." Crick was also an advocate for the establishment of Darwin Day as a British national holiday.
== Recognition == Lederer received the 1951 Ernest Guenther Award, the 1964 Paul Karrer Gold Medal and Lecture, the 1964 August Wilhelm von Hofmann Medal, the 1974 CNRS Gold Medal, the 1976 M. S. Tswett chromatography medal (alongside V. Pretorius, A. T. James, G. Guiochon, and M. J. E. Golay), and a 1982 Robert Koch Gold Medal. He was elected as a member of the French Academy of Sciences in 1982, and was a member of 8 foreign academies, including the Austrian Academy of Sciences. He joined the German National Academy of Sciences Leopoldina in 1961. In 2018, a building on the la Doua campus of Claude Bernard University Lyon 1 was named after him.
Plutonium-239 emits alpha particles to become uranium-235. As an alpha emitter, plutonium-239 is not particularly dangerous as an external radiation source, but if it is breathed in as dust it is very dangerous and carcinogenic. It has been estimated that a pound (454 grams) of plutonium inhaled as plutonium oxide nano-particles sized to enter and remain in the lungs could give cancer to two million people. However, this estimate is based on the dose-linear no-threshold model which has been criticised. Orally ingested plutonium is by far less dangerous as only a tiny fraction is absorbed from the gastrointestinal tract; 800 mg would be unlikely to cause a major health risk as far as radiation is concerned. As a heavy metal, plutonium is also chemically toxic.
Sources: en.wikipedia.org
=== Criminal justice === Kennedy opposed the First Step Act, a bipartisan criminal justice reform bill. The bill passed 87–12 on December 18, 2018. Kennedy said the bill did not do enough to protect victims of crime, saying, "This is not a criminal justice bill. It is a prisoner release bill. We should be protecting victims of crimes and not the offenders who committed the crimes." In 2023, he introduced a bill that would lower the amount of fentanyl a dealer must possess to face the mandatory minimum prison sentence. Kennedy has criticized prosecutors for declining to prosecute some offenders. In 2023, he introduced the Prosecutors Need to Prosecute Act, which requires prosecutors to disclose when they decline to prosecute cases. It would also remove funding for prosecutors who fail to report such cases.
== Mechanism == Phosphorylation involves the transfer of phosphate groups from ATP to the enzyme, the energy for which comes from hydrolysing ATP into ADP or AMP. However, dephosphorylation releases phosphates into solution as free ions, because attaching them back to ATP would require energy input. Cysteine-dependent phosphatases (CDPs) catalyse the hydrolysis of a phosphoester bond via a phospho-cysteine intermediate.
==== National League runs scored record (2000) ==== In a presentation of rankings of active major leaguers prior to the 2000 season, Sports Illustrated slotted Bagwell second among position players behind Ken Griffey Jr., and The Sporting News placed him sixth among all players, including pitchers. Bagwell christened the team's 2000 move to Enron Field (later renamed Minute Maid Park) with the stadium's first-ever hit and first two runs driven in, in a 6–5 exhibition victory over the New York Yankees on March 30. His two-run, ninth-inning home run against Trevor Hoffman in San Diego on June 10 won the contest for Houston, 7–6, and stopped a 10-game road losing streak. On August 14 in Philadelphia, he homered twice and tied a club record with seven RBI in a 14–7 win, shared by Rafael Ramírez and Pete Incaviglia. Five days later against Milwaukee, Bagwell again homered twice for the 299th and 300th of his career; the second home run broke an eighth-inning tie to give Houston a 10–8 win. He joined Hank Aaron, Joe DiMaggio, Frank Robinson and Ted Williams as the fifth player in major league history to record 300 home runs, 1,000 RBI and 1,000 runs scored in his first ten seasons. Bagwell finished the 2000 season with a career-high 47 home runs, .310 average, .424 OBP, .615 SLG (the second-best mark of his career) for a 152 OPS+. His 152 runs scored was the highest total in a season since Lou Gehrig in 1936, and his 295 runs scored from 1999 to 2000 set a National League two-season record.
The relaxin receptors are a subclass of four closely related G protein-coupled receptors (GPCR) that bind relaxin peptide hormones. Below is list of human relaxin receptors, their endogenous peptide hormones, and what downstream enzymes are activated or inhibited by the receptor.
Sources: en.wikipedia.org
== Purpose == Pharmacokinetics simulation gives an insight to drug efficacy and safety before exposure of individuals to the new drug that might help to improve the design of a clinical trial. Pharmacokinetics simulations help in addition in therapy planning, to stay within the therapeutic range under various physiological and pathophysiological conditions, e.g., chronic kidney disease.
24 January The discovery of 85 exoplanet candidates based on data from the TESS observatory is reported. All have orbital periods of between 20 and 700 days, with temperatures similar to those of Solar System planets. A global analysis of groundwater levels reports rapid declines of over 0.5 meters per year are widespread and that declines have accelerated over the past four decades in 30% of the world's regional aquifers. The study also shows cases in which depletion trends have reversed following interventions such as policy changes. 25 January – The Laser Interferometer Space Antenna (LISA) is given the go-ahead by the European Space Agency (ESA). It will launch in 2035. 26 January – Astronomers report the detection of water vapor in the atmosphere of GJ 9827 d, an exoplanet about twice the size of Earth. 29 January Elon Musk's startup Neuralink implants their first microchip into a human brain. A robotic sensor able to read braille with 87.5% accuracy and at twice the speed of a human is demonstrated. 31 January – NASA reports the discovery of a super-Earth called TOI-715 b, located in the habitable zone of a red dwarf star about 137 light-years away. Promising innovations relating to global challenges are reported: a self-powered solar panel cleaning system using an electrodynamic screen, removing contaminants through high-voltage electric fields, is demonstrated (4 Jan), an atmospheric water generator (WaterCube) for humidity levels above 40% is released (9 Jan).
=== Puberty === Puberty is the onset of the ability to reproduce, and takes place over two to three years, producing a number of changes. The structures of the vulva become proportionately larger and may become more pronounced. Pubarche, the first appearance of pubic hair develops, firstly on the labia majora, and later spreads to the mons pubis, and sometimes to the inner thighs and perineum. Pubic hair is much coarser than other body hair, and is considered a secondary sex characteristic. Pubarche can occur independently of puberty. Premature pubarche may sometimes indicate a later metabolic-endocrine disorder seen at adolescence. The disorder sometimes known as a polyendocrine disorder is marked by elevated levels of androgen, insulin, and lipids, and may originate in the fetus. Instead of being seen as a normal variant it is proposed that premature pubarche may be seen as a marker for these later endocrine disorders. Apocrine sweat glands secrete sweat into the pubic hair follicles. This is broken down by bacteria on the skin and produces an odor, which some consider to act as an attractant sex pheromone. The labia minora may grow more prominent and undergo changes in color. At puberty, the first monthly period known as menarche marks the onset of menstruation. In prepubertal girls, the skin of the vulva is thin and delicate, and its neutral pH makes it prone to irritation. The production of the female sex hormone estradiol (an estrogen) at puberty, causes the perineal skin to thicken by keratinising, and this reduces the risk of infection.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.